Last Updated: 09 Nov 2024
Executive Summary
Apellis Pharmaceuticals Inc. (APLS) is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds that inhibit the complement system for the treatment of autoimmune and inflammatory diseases. The company has a strong pipeline of product candidates, including pegcetacoplan, which is currently in Phase 3 clinical trials for the treatment of geographic atrophy (GA), a leading cause of blindness. APLS has a market capitalization of $3.73 billion and a 52-week price range of $24.34 to $73.80. The latest stock price is $29.98.
Company Overview
Apellis Pharmaceuticals was founded in 2009 and is headquartered in Waltham, Massachusetts. The company's mission is to develop innovative therapies that improve the lives of patients with autoimmune and inflammatory diseases. APLS has a team of experienced scientists and researchers who are dedicated to advancing the science of complement inhibition.
Fundamental Analysis
Apellis Pharmaceuticals has a strong financial position. The company has $1.1 billion in cash and equivalents and no debt. APLS is also generating revenue, with total revenue of $715.2 million in the past twelve months. The company is expected to continue to grow revenue in the future, with analysts estimating revenue of $1.2 billion in 2024.
Apellis Pharmaceuticals is not yet profitable, but the company is expected to become profitable in the future. Analysts estimate that APLS will have earnings per share of $0.10 in 2024.
Technical Analysis
The technical analysis of Apellis Pharmaceuticals stock shows that the stock is in a downtrend. The stock price has been falling since early 2023, and it is now trading below its 50-day and 200-day moving averages. The relative strength index (RSI) is also below 50, which indicates that the stock is oversold.
Short Term Outlook
The short-term outlook for Apellis Pharmaceuticals stock is negative. The stock is in a downtrend, and it is likely to continue to fall in the near term. Investors should avoid buying APLS stock until the stock price shows signs of a reversal.
Long Term Outlook
The long-term outlook for Apellis Pharmaceuticals stock is positive. The company has a strong pipeline of product candidates, and it is expected to become profitable in the future. Investors who are willing to take on some risk may want to consider buying APLS stock for the long term.
Analyst Recommendations
Analysts are divided on Apellis Pharmaceuticals stock. Seven analysts have a strong buy rating on the stock, seven have a buy rating, four have a hold rating, and zero have a sell or strong sell rating. The average analyst target price is $46.22.
